Loading...
•
Mar 31, 2024
Optinose Q1 2024 Earnings Report
Optinose reported financial results for the quarter ended March 31, 2024.
Key Takeaways
Optinose reported a 26% increase in XHANCE net revenue, reaching $14.9 million for Q1 2024, compared to $11.8 million in Q1 2023. The company expects full year 2024 XHANCE net revenues to be between $85.0 to $95.0 million and anticipates positive income from operations (GAAP) for full year 2025.
XHANCE was approved by the FDA as the first prescription medication for chronic rhinosinusitis without nasal polyps.
The new indication expands the total addressable market by up to ten times.
The company completed a registered direct offering expected to result in approximately $55 million of net proceeds.
Optinose expects full year 2024 XHANCE net revenues to be between $85.0 to $95.0 million.
Optinose
Optinose
Optinose Revenue by Segment
Revenue by Segment
Specialty Pharmaceuticals Revenue
CapyFin.com Forward Guidance
Optinose expects XHANCE net revenues for the full year of 2024 to be between $85.0 to $95.0 million. They also anticipate positive income from operations (GAAP) for full year 2025.
Positive Outlook
- XHANCE net revenues for the full year of 2024 to be between $85.0 to $95.0 million.
- Full year 2024 XHANCE average net revenue per prescription to exceed $230.
- To product positive income from operations (GAAP) for full year 2025.
- Peak year XHANCE net revenues will be at least $300 million from its current specialist physician audience.
- Post-offering cash and cash equivalents of approximately $100 million will be sufficient to fund its operations and debt service obligations through 2025.
Challenges Ahead
- Total GAAP operating expenses for 2024 to be between $95.0 to $101.0 million.
- Stock-based compensation for 2024 to be approximately $6.0 million.
- Physician and patient acceptance of XHANCE for its new indication.
- The Company’s ability to maintain adequate third-party reimbursement for XHANCE (including its new indication).
- The prevalence of chronic sinusitis and market opportunities for XHANCE may be smaller than expected.